ArticleThe lancet. Diabetes & endocrinology2017
Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys.
Article in The lancet. Diabetes & endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03512691 (The Nueva Ecija Cardiovascular Risk Experiment), which is not on this map. Cited by 82 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Nueva Ecija Cardiovascular Risk Experiment: An Evaluation of the Impact of Risk Information and Screening on Primary Prevention of Cardiovascular Disease
Who cites it
82 citing papers in PubMed, 4 syntheses or guidelines pooled it, 147 citations in OpenAlex.
- Discrimination and calibration performances of non-laboratory-based and laboratory-based cardiovascular risk predictions: a systematic review.Open heart · 2025Pooled it
- Pooled it
- Risk scores for type 2 diabetes mellitus in Latin America: a systematic review of population-based studies.Diabetic medicine : a journal of the British Diabetic Association · 2019Pooled it
- Cardiovascular Disease Prognostic Models in Latin America and the Caribbean: A Systematic Review.Global heart · 2019Pooled it
- Effects of the Chinese Heart-Healthy Diet (Sichuan Cuisine Version) on the 10-year CVD risk and vascular age: a randomised controlled feeding trial.The British journal of nutrition · 2024Trial
- Waiting for JAK inhibitor safety data.RMD open · 2022Trial
- Composite cardiovascular risk and BMI affected comparative profiles of BIAsp 30 + metformin vs BIAsp 30 monotherapy: a MERIT post-hoc analysis.Scientific reports · 2021Trial
- Comparing Non-Laboratory-Based and Laboratory-Based Cardiovascular Risk Predictions: Systematic Review and Meta-Analysis.Health science reports · 2026Review
- Anthropometric Indices Associated With Elevated Estimated 10-year Risk of Cardiovascular Disease Among Adults in the Kumasi Metropolis of Ghana: A Cross-Sectional Study.Health science reports · 2026Article
- High-Density Lipoprotein Treatment Effectively Protected the Endothelial Cells, Mitochondria and Myocardium Against Oxidized Low-Density Lipoprotein Damage.Acta Cardiologica Sinica · 2026Article
- Estimating investment costs to improve hypertension care in Lagos, Nigeria.Communications medicine · 2026Article
- External validation and recalibration of cardiovascular risk scores for prediction of 10-year risk of fatal cardiovascular disease: a prospective, observational, population-based cohort analysis of adults in Mexico City.Lancet regional health. Americas · 2026Article
- Cardiovascular risk scores, non-invasive vascular measures and myositis damage index reveal increased cardiovascular risk in idiopathic inflammatory myopathies: a case-control study.BMC rheumatology · 2026Article
- Impact of a Contextualized Workplace Intervention in a Latino Population on Reducing Cardiovascular Risk and Its Associated Factors.Journal of clinical medicine · 2026Article
- Article
- Consensus Conference Series on Dysglycemia-Based Chronic Disease (DBCD) in Latin America: The Chilean Transculturalization.Annals of global health · 2026Article
- Machine learning for predicting cardiovascular events in older adults with type 2 diabetes using Medicare claims and electronic health records.Journal of clinical epidemiology · 2025Article
- External validation and recalibration of office- and laboratory-based cardiovascular risk scores for prediction of 10-year risk of fatal cardiovascular disease in 112,262 adults in Mexico City.medRxiv : the preprint server for health sciences · 2025Article
- Cardiovascular Risk Prediction in Older Adults.Current atherosclerosis reports · 2025Review
- Reduced insulin use and diabetes complications upon introduction of SGLT-2 inhibitors and GLP1-receptor agonists in low- and middle-income countries: A microsimulation.PLoS medicine · 2025Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
36 authors at 20 institutions in 16 countries.
Funding
Abstract
backgroundWorldwide implementation of risk-based cardiovascular disease (CVD) prevention requires risk prediction tools that are contemporarily recalibrated for the target country and can be used where laboratory measurements are unavailable. We present two cardiovascular risk scores, with and without laboratory-based measurements, and the corresponding risk charts for 182 countries to predict 10-year risk of fatal and non-fatal CVD in adults aged 40-74 years.
methodsBased on our previous laboratory-based prediction model (Globorisk), we used data from eight prospective studies to estimate coefficients of the risk equations using proportional hazard regressions. The laboratory-based risk score included age, sex, smoking, blood pressure, diabetes, and total cholesterol; in the non-laboratory (office-based) risk score, we replaced diabetes and total cholesterol with BMI. We recalibrated risk scores for each sex and age group in each country using country-specific mean risk factor levels and CVD rates. We used recalibrated risk scores and data from national surveys (using data from adults aged 40-64 years) to estimate the proportion of the population at different levels of CVD risk for ten countries from different world regions as examples of the information the risk scores provide; we applied a risk threshold for high risk of at least 10% for high-income countries (HICs) and at least 20% for low-income and middle-income countries (LMICs) on the basis of national and international guidelines for CVD prevention. We estimated the proportion of men and women who were similarly categorised as high risk or low risk by the two risk scores.
findingsPredicted risks for the same risk factor profile were generally lower in HICs than in LMICs, with the highest risks in countries in central and southeast Asia and eastern Europe, including China and Russia. In HICs, the proportion of people aged 40-64 years at high risk of CVD ranged from 1% for South Korean women to 42% for Czech men (using a ≥10% risk threshold), and in low-income countries ranged from 2% in Uganda (men and women) to 13% in Iranian men (using a ≥20% risk threshold). More than 80% of adults were similarly classified as low or high risk by the laboratory-based and office-based risk scores. However, the office-based model substantially underestimated the risk among patients with diabetes.
interpretationOur risk charts provide risk assessment tools that are recalibrated for each country and make the estimation of CVD risk possible without using laboratory-based measurements.
fundingNational Institutes of Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.